Why the study?
Does dobutamine improve contractility and ejection fraction in male patients with moderately severe left heart failure after acute myocardial infarction?
Does dobutamine improve contractility and ejection fraction in male patients with moderately severe left heart failure after acute myocardial infarction?
While dobutamine improves contractility and ejection fraction in patients with heart failure post-AMI, its significant positive chronotropic effect limits its clinical utility in this setting.
Answers are grounded in this paper and cite their sources.
May limit dobutamine utility in post-MI HF; hypothesis-generating for net benefit in larger cohorts.
Dobutamine, a new positive inotropic drug, was given as i.v. infusion at a rate of 2.5--7.5 micrograms/kg/min to nine male patients with a moderately severe left heart failure. The patients were treated in our CCU for acute myocardial infarction (AMI) and had PEP/LVET above 0.40 on routine registrations of systolic time intervals, PEP (preejection phase), PEPI (PEP corrected for heart rate), LVET (left ventricular ejection time) and LVETI (LVET corrected for heart rate). Dobutamine increased contractility, measured as shortening of PEP and PEPI, and also increased ejection fraction, measured as PEP/LVET. Concomitantly, heart rate increased significantly but no changes were noted in systolic or diastolic BPs. The positive inotropic effect of dobutamine was thus accompanied by a positive chronotropic effect, which limits the usefulness of the drug in patients with recent AMI.
No takes yet. Share an insight, caveat, or question.
Rehnqvist et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: